Page last updated: 2024-09-05

orbofiban and Cardiac Failure

orbofiban has been researched along with Cardiac Failure in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	2 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Buros, JL; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; O'Donoghue, M; Sabatine, MS	1
Braunwald, E; Cannon, CP; de Lemos, JA; McCabe, CH; Morrow, DA; Murphy, S; Rifai, N; Sabatine, MS; Scirica, BM; Wiviott, SD	1
Ferguson, JJ	1

Trials

2 trial(s) available for orbofiban and Cardiac Failure

Article	Year
Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation, 2006, Aug-08, Volume: 114, Issue:6 Topics: Acute Disease; Adult; Alanine; Biomarkers; Fatty Acid-Binding Proteins; Female; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Natriuretic Peptide, Brain; Odds Ratio; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Pyrrolidines; Risk Factors; Troponin I	2006
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clinical chemistry, 2007, Volume: 53, Issue:10 Topics: Acute Disease; Aged; Alanine; Angina Pectoris; Angina, Unstable; C-Reactive Protein; Coronary Disease; Female; Follow-Up Studies; Heart Failure; Humans; Male; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Recurrence; Risk; Syndrome	2007

Article

Year

Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes.

Circulation, 2006, Aug-08, Volume: 114, Issue:6

Topics: Acute Disease; Adult; Alanine; Biomarkers; Fatty Acid-Binding Proteins; Female; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Natriuretic Peptide, Brain; Odds Ratio; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Pyrrolidines; Risk Factors; Troponin I

2006

Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.

Clinical chemistry, 2007, Volume: 53, Issue:10

Topics: Acute Disease; Aged; Alanine; Angina Pectoris; Angina, Unstable; C-Reactive Protein; Coronary Disease; Female; Follow-Up Studies; Heart Failure; Humans; Male; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Recurrence; Risk; Syndrome

2007

Other Studies

1 other study(ies) available for orbofiban and Cardiac Failure

Article	Year
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology. Circulation, 1999, Aug-10, Volume: 100, Issue:6 Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Monoclonal; Aspirin; Benzamidines; Biphenyl Compounds; Cardiology; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Disease; Dalteparin; Defibrillators, Implantable; Double-Blind Method; Enalapril; Endothelial Growth Factors; Fatty Acids, Omega-3; Guanidines; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Laser Therapy; Lymphokines; Metoprolol; Multicenter Studies as Topic; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pyrrolidines; Randomized Controlled Trials as Topic; Simvastatin; Sodium-Hydrogen Exchangers; Stents; Sulfones; Thrombolytic Therapy; Ticlopidine; Tissue Plasminogen Activator; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vitamin E	1999

Article

Year

Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.

Circulation, 1999, Aug-10, Volume: 100, Issue:6

Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Monoclonal; Aspirin; Benzamidines; Biphenyl Compounds; Cardiology; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Disease; Dalteparin; Defibrillators, Implantable; Double-Blind Method; Enalapril; Endothelial Growth Factors; Fatty Acids, Omega-3; Guanidines; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Laser Therapy; Lymphokines; Metoprolol; Multicenter Studies as Topic; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pyrrolidines; Randomized Controlled Trials as Topic; Simvastatin; Sodium-Hydrogen Exchangers; Stents; Sulfones; Thrombolytic Therapy; Ticlopidine; Tissue Plasminogen Activator; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vitamin E

1999